Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Berman

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
NPJ Breast Cancer|July 19, 2025
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapyJesús Fuentes-Antrás, Mitchell J Elliott, Sasha C Main, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast CancerMitchell J Elliott, Karen Howarth, Sasha Main, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Cell Reports|October 26, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Cell Reports|October 17, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
The Journal of Clinical Investigation|February 2, 2021
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumorsParasvi S Patel, Karan Joshua Abraham, Kiran Kumar Naidu Guturi, et al.
Cancer Cell|January 27, 2015
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progressionIsaac S Harris, Aislinn E Treloar, Satoshi Inoue, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
NPJ Breast Cancer|July 19, 2025
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapyJesús Fuentes-Antrás, Mitchell J Elliott, Sasha C Main, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast CancerMitchell J Elliott, Karen Howarth, Sasha Main, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Cell Reports|October 26, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Cell Reports|October 17, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
The Journal of Clinical Investigation|February 2, 2021
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumorsParasvi S Patel, Karan Joshua Abraham, Kiran Kumar Naidu Guturi, et al.
Cancer Cell|January 27, 2015
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progressionIsaac S Harris, Aislinn E Treloar, Satoshi Inoue, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Pageof 12